☆ 4.8 Article

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

NATURE MEDICINE (2021)

Related references

Note: Only part of the references are listed.

Review Hematology

How should we use convalescent plasma therapies for the management of COVID-19?

Erica M. Wood et al.

Summary: Convalescent plasma from blood donors with antibodies to SARS-CoV-2 may benefit COVID-19 patients by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal characteristics, transfusion volume, and administration timing remain to be determined, requiring international collaborative efforts to establish clinical efficacy. Preliminary safety data for COVID-19 CP is encouraging, with ongoing large, high-quality randomized trials starting to report preliminary results.

BLOOD (2021)

Add to Collection

Article Immunology

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Alexandra Schafer et al.

Summary: The study shows that combined use of hu-mAbs is effective for prevention and therapy of SARS-CoV-2 infection, but in vivo protection is influenced by intact effector function.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Emma S. Winkler et al.

Summary: This study found that neutralizing human monoclonal antibodies in SARS-CoV-2-infected animals require Fc effector functions for optimal protection, reducing inflammation, improving respiratory mechanics, and being associated with diminished immune signaling and tissue repair.

CELL (2021)

Add to Collection

Article Hematology

High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples

Sai Priya Anand et al.

Summary: Research found that antibodies targeting the full-length SARS-CoV-2 Spike gradually decline after infection resolution, not influenced by the number of donations but strongly correlated with the decline of RBD-specific antibodies and the number of days post-symptom onset.

TRANSFUSION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Naveenchandra Suryadevara et al.

Summary: The study found that a subset of human monoclonal antibodies derived from convalescent SARS-CoV-2 patients possess neutralizing activity, with two antibodies capable of inhibiting infection. Mechanistic studies revealed these antibodies neutralize in part by inhibiting post-attachment steps in the infection cycle.

CELL (2021)

Add to Collection

Article Critical Care Medicine

Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial*

Elliott Bennett-Guerrero et al.

Summary: This study found that administration of convalescent plasma to hospitalized patients with coronavirus disease 2019 infection did not improve outcomes, despite convalescent plasma having high neutralizing activity and increasing antibodies to severe acute respiratory syndrome coronavirus 2.

CRITICAL CARE MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): updates study protocol for an international, multicentre, randomized, open-label trial

Philippe Begin et al.

Summary: CONCOR-1 is a randomized controlled trial investigating the efficacy and safety of COVID-19 convalescent plasma in patients with SARS-CoV-2 infection, with the primary outcome being intubation or death at day 30. The trial will also provide information on the role and thresholds of SARS-CoV-2 antibody titres and neutralization assays for donor qualification.

TRIALS (2021)

Add to Collection

Article Multidisciplinary Sciences

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

Manaf AlQahtani et al.

Summary: The pilot study suggests that CP therapy is safe in hospitalized COVID-19 patients, but there were no significant differences in primary and secondary outcome measures compared to standard therapy. A larger definitive study is needed for confirmation.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Infectious Diseases

Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial

F. W. Hamilton et al.

Summary: This study highlights the potential benefit of convalescent plasma in reducing mortality among COVID-19 patients, with varying effectiveness based on antibody status and timing of presentation. Patients who present within 7 days without detectable antibodies may experience a significant mortality reduction, while those already with antibodies may not derive as much benefit from convalescent plasma therapy. Bayeisan analysis provides valuable insights into treatment efficacy compared to traditional frequentist methods.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

Arvind Gharbharan et al.

Summary: A clinical trial on 86 COVID-19 patients treated with convalescent plasma showed no overall clinical benefit, as most patients already had potent antibodies upon admission, leading to the trial being terminated prematurely.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Cell Biology

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

Sai Priya Anand et al.

Summary: Recent research on convalescent individuals of COVID-19 has shown a decline in antibody levels in plasma, while specific memory B cells remain present. IgM antibodies against Spike and RBD decay rapidly, whereas IgG decline is less significant. Understanding these immune memory responses is crucial for secondary infection prevention and vaccine efficacy.

CELL REPORTS MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Neutralizing Antibody LY-CoV555 for Outpatient Covid-19

Arturo Casadevall et al.

Summary: Research indicates that the antiviral activity of the monoclonal antibody LY-CoV555 was highest at the middle dose when treating patients with Covid-19. Additionally, there may be a correlation between dosage and efficacy, suggesting the possibility of dosage-dependent effects on the monoclonal antibody's efficacy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis

Niveditha Devasenapathy et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)

Add to Collection

Article Hematology

How did we rapidly implement a convalescent plasma program?

Alexandra Budhai et al.

TRANSFUSION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial

Ling Li et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Hematology

Rapid establishment of aCOVID-19 convalescent plasma program in a regional health care delivery network

Douglas Blackall et al.

TRANSFUSION (2020)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Anup Agarwal et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Microbiology

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Jeffrey Seow et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

A simple protein-based surrogate neutralization assay for SARS-CoV-2

Kento T. Abe et al.

JCI INSIGHT (2020)

Add to Collection

Article Hematology

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset

Josee Perreault et al.

BLOOD (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

Tomer Zohar et al.

CELL (2020)

Add to Collection

Article Anesthesiology

Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study

Ossama Hamdy Salman et al.

EGYPTIAN JOURNAL OF ANAESTHESIA (2020)

Add to Collection

Article Multidisciplinary Sciences

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

Georgia D. Tomaras et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Add to Collection

Article Medicine, General & Internal

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

Barton F. Haynes et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Hematology

Transfusion-associated circulatory overload after plasma transfusion

Christina Narick et al.

TRANSFUSION (2012)

Add to Collection

Article Statistics & Probability

Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models

Simon N. Wood

JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2011)

Add to Collection

Article Computer Science, Interdisciplinary Applications

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

Paul A. Harris et al.

JOURNAL OF BIOMEDICAL INFORMATICS (2009)

Add to Collection

Article Immunology

More is not necessarily better: Prozone-like effects in passive immunization with IgG

CP Taborda et al.

JOURNAL OF IMMUNOLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.